How COVID Rewrote Everything Doctors Thought They Knew About Mast Cells

For the first 25 years of my career, mast cells were an allergy story.

They were the cells behind sneezing, wheezing, hives, and anaphylaxis. They responded to allergens — pollen, pet dander, peanuts — through well-understood IgE receptors. We knew their mechanism. We knew their triggers. It was, from an immunology standpoint, a relatively tidy narrative.

Then COVID happened, and the narrative broke.

What COVID Exposed About Mast Cells

I started seeing patients during the pandemic who had never had an allergic reaction in their lives. Now they were down to eating four or five foods because everything else was making them sick. They couldn’t enter a hotel lobby with air freshener. They were reacting to perfumes, car exhaust, cleaning products they’d used for years without issue.

These weren’t allergic people with a new allergy. Something had been fundamentally destabilized.

What became clear — and what the science has since supported — is that mast cells are not just allergy cells. They are the primary immune sentinel in tissue, and they respond to a far broader range of threats than we had appreciated.

Mast cells are not found in blood. They live in tissue — nasal passages, lungs, gut lining, skin, brain, heart, and reproductive organs. They’re your body’s first responders at the interface between your internal systems and the outside world. When they detect a threat — trauma, infection, toxin, chemical, or even sustained psychological stress — they release a cascade of chemical mediators: histamine, tryptase, prostaglandins, interleukins.

Because mast cells aren’t measured in routine bloodwork (you’d need tissue biopsies), they had been largely invisible to mainstream clinical medicine. COVID made them impossible to ignore.

How COVID Activates Mast Cells

The SARS-CoV-2 virus carries a spike protein that was, in the early hypothesis of many researchers, likely engineered — which is part of why it spread so efficiently and triggered such severe immune responses.

The spike protein, when it enters the body, triggers an intense response from monocytes — a type of white blood cell circulating in the blood. Those monocytes then go on to activate mast cells in tissue. The result is widespread mast cell dysregulation: cells that should be calm are firing repeatedly, releasing their mediators into tissue throughout the body.

This explains the multi-system symptoms of both acute COVID and long COVID. Skin, gut, brain, cardiovascular system — mast cells are present in all of them, and when they’re dysregulated simultaneously, the symptom picture is bewildering and multi-organ.

Why Antihistamines Were Helping Long COVID Patients

Early in the pandemic, reports started emerging of long-haul COVID patients who were getting significant symptom relief from antihistamines — H1 blockers like cetirizine, and H2 blockers like famotidine. At the time, I’ll admit it puzzled me. Long COVID wasn’t an allergy. Why would antihistamines help?

The answer, as the mast cell connection became clearer: the antihistamines weren’t treating an allergy. They were blocking the downstream effects of mast cell-derived histamine — the histamine released by dysregulated mast cells responding to the spike protein-triggered cascade. It wasn’t an allergy mechanism at all. It was a mast cell activation mechanism that happened to respond to the same medications.

This is now supported by research from the University of Pennsylvania and other academic centers that have looked specifically at post-COVID mast cell activation.

The Vaccine Connection

The COVID vaccine was developed using the spike protein — specifically to induce immunity against the virus. In most people, this worked as intended.

But in some patients — particularly those who may have had unrecognized mast cell predispositions, or who received high levels of exposure to the spike protein through vaccination — the vaccine triggered a similar mast cell activation cascade. The spike protein, whether delivered by infection or by vaccination, can stimulate the monocyte-to-mast cell activation pathway.

This is a smaller subset of patients than those affected by COVID infection itself — in my practice, currently around 10 to 20 percent of new MCAS presentations have a COVID or vaccine trigger, down from a higher proportion a few years ago. But it’s a real phenomenon that requires clinical acknowledgment.

Post-COVID MCAS and POTS

One of the most challenging post-COVID presentations involves POTS — postural orthostatic tachycardia syndrome. When a patient with post-COVID MCAS stands up, their heart rate spikes and their blood pressure may drop. This is a form of dysautonomia — a disorder of the autonomic nervous system — and it’s profoundly disabling.

Approximately 20 to 30 percent of the MCAS patients in my practice also present with POTS or POTS-like symptoms. This percentage is higher in patients with Ehlers-Danlos syndrome (EDS), a connective tissue disorder associated with hypermobile joints that has a strong overlap with both MCAS and POTS.

For post-COVID POTS, my approach incorporates the mast cell stabilization protocol alongside medications specifically for the autonomic dysregulation, including beta blockers. In some patients, I also use gamma globulin injections — based on work from the University of Pennsylvania — to address the interferon-driven inflammatory cascade that underlies the autonomic dysfunction. Some patients show improvement in POTS symptoms as mast cell stability is achieved; others require more targeted management.

Brain Fog: Finally Taken Seriously

Before COVID, brain fog was frequently dismissed by conventional medicine. Patients were told it wasn’t a real diagnosis. It was vague, unmeasurable, and didn’t fit into established categories.

COVID changed that. Research published in major medical journals has now demonstrated that brain fog in long COVID patients reflects genuine neuroinflammation — visible on imaging, mechanistically explainable — driven by immune activity affecting neurons, not by lingering viral infection.

In my view, the same mechanism operates in mast cell activation syndrome, candida, and toxic mold illness. The mast cells are in the brain. Histamine receptors are in the brain. When these systems are dysregulated, the neurological symptoms — fog, anxiety, poor memory, migraine — are real and physiologically grounded.

How Patients Are Finding the Right Diagnosis

One thing I’ve noticed in recent years: patients are increasingly arriving with MCAS as a self-identified concern. They’ve seen multiple specialists, been dismissed or told their labs are normal, and turned to AI tools — ChatGPT, Claude, Gemini — to enter their multi-system symptoms and get a differential diagnosis.

These tools are surfacing MCAS with increasing frequency when patients describe simultaneous skin, GI, neurological, and cardiovascular symptoms with no clear allergic cause. I find this encouraging. These patients have often been suffering for years. Anything that helps them find their way to the right clinical conversation sooner is valuable.

Frequently Asked Questions

Q: Did COVID create MCAS in people who didn’t have it before?

Yes. COVID infection — likely through the spike protein’s activation of monocytes, which then activate mast cells — appears to trigger genuine MCAS in people with no prior allergic history. This represents a new understanding of what mast cell activation syndrome is and who it affects.

Q: Can the COVID vaccine cause MCAS?

In some patients, yes. The vaccine’s spike protein can activate a similar monocyte-to-mast cell pathway as the infection itself. This is a smaller subset of patients, but it’s a documented and clinically significant phenomenon.

Q: Is post-COVID MCAS treated the same way as non-COVID MCAS?

The stabilization protocol is largely the same. Post-COVID cases may require additional interventions — such as gamma globulin injections for the interferon cascade — particularly when POTS is present.

Q: Why did antihistamines help some long COVID patients?

Antihistamines were reducing the effects of histamine released by dysregulated mast cells — not treating an allergy. The mechanism is mast cell-mediated, not IgE-mediated, which is why this clinical observation pointed researchers toward the mast cell connection in long COVID.